The recently published CANTOS study showed that anti-IL-1β therapy leads to a lower rate of recurrent cardiovascular events [18] and that anti-IL-1β therapy reduces the risk of and mortality from lung cancer in patients with atherosclerosis [69], supporting the concept of persistent inflammation as a pathological driver in disease networks. Here, IL1B is linked to lung cancer.